



## **vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions**

June 11, 2017

*Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints*

HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of Type 2 diabetes, were presented at the American Diabetes Association 77<sup>th</sup> Scientific Sessions.

In a poster presentation titled, "Is Less More? Learning to dose the oral, non-peptide GLP-1R Agonist, TTP273 in Type 2 Diabetics," researchers from vTv reviewed results from a concentration/effect analysis on the LOGRA study showing that lower doses of TTP273 may show more pronounced effects for key efficacy endpoints, including a reduction in HbA1c, weight and fasting plasma glucose. The characteristics of TTP273 (functionally biased and neuro-endocrine signaling) provide a potential scientific rationale supporting the concept that for TTP273, less may be more.

"Further analysis of the Phase 2 data has highlighted a trend where a lower dose shows more pronounced effects," said Steve Holcombe, president and chief executive officer of vTv Therapeutics. "While additional clinical investigation is needed to confirm the optimal dose for TTP273, we are enthusiastic about TTP273's potential to meaningfully expand the treatment options for patients with Type 2 diabetes."

TTP273-201 is a 12-week, multi-center Phase 2, double-blind, placebo-controlled randomized study of 174 patients with Type 2 diabetes on stable doses of metformin who were randomized to either placebo or TTP273 (150 mg once (QPM) or twice (BID) daily). Baseline characteristics were well balanced amongst groups with an overall mean age of 56 years, mean HbA1c of 8.6% and mean BMI of 32 kg/m<sup>2</sup>. TTP273 was well tolerated with no severe hypoglycemia adverse events (AEs). The most common TEAE was diarrhea, mostly mild in intensity, with only one subject discontinued due to mild diarrhea (150 mg BID). Less nausea was observed in active groups than placebo and the only incidence of vomiting occurred with placebo dosing. Once daily dosing of TTP273 demonstrated placebo-subtracted decrease from baseline of 0.9% in HbA1c and 0.9 kg in weight.

A copy of the presentation will be made available in the [News & Events](#) section of the Company's website following the presentation.

### **About TTP273**

TTP273 is an oral small molecule that works by activating the GLP-1 receptor. Activation of the GLP-1 receptor leads to the enhancement of insulin secretion and suppression of glucagon production and decreased food intake.

There are currently several marketed injectable GLP-1 therapies. These agents have demonstrated notable glucose lowering in addition to weight loss; however, their widespread use may be hindered by the route of administration (injection) and by the high incidence of gastrointestinal side effects (nausea and vomiting).

### **About Type 2 Diabetes**

Type 2 diabetes is a result of the body's inability to use insulin properly to control sugar in the bloodstream. Type 2 diabetes represents up to 95% of diabetes patients, imposing a growing burden on healthcare systems globally. Diabetes remains the 7th leading cause of death in the United States, costing the healthcare system \$245 billion annually. According to the American Diabetes Association, there are 29.1 million Americans, or 9.3% of the population, living with diabetes.

### **About vTv Therapeutics Inc.**

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness. Last month, vTv announced positive topline results from a placebo and active-comparator-controlled Phase 2b clinical study of TTP399, a liver-selective glucokinase activator (GKA) under development for the treatment of Type 2 diabetes.

The Company's drug candidates were discovered with its high-throughput drug discovery platform, TTP Translational Technology®, which translates the functional modulation of human proteins into safe and effective medicines. For further company information, visit [www.vtvtherapeutics.com](http://www.vtvtherapeutics.com).

### **Forward-Looking Statements**

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170611005037/en/>

Source: vTv Therapeutics Inc.

vTv Therapeutics Inc.

**Investors**

Michael Gibraltar, 646-378-2938

[IR@vtvtherapeutics.com](mailto:IR@vtvtherapeutics.com)

or

**Media**

Pure Communications Inc.

Katie Engleman, 910-509-3977

[Katie@purecommunications.com](mailto:Katie@purecommunications.com)